Back

Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review

2020-04-24 pharmacology and therapeutics Title + abstract only
View on medRxiv
Show abstract

The risk-benefit ratio associated with the use of repurposed drugs to treat 2019 SARS-CoV-2 related infectious disease (COVID-19) is complicated since benefits are awaited, not proven. A thorough literature search was conducted to source information on the pharmacological properties of 5 drugs and 1 combination (azithromycin, chloroquine, favipiravir, hydroxychloroquine, remdesivir, and lopinavir/ritonavir) repurposed to treat COVID-19. A risk assessment of drug-induced Long QT Syndrome (LQTS) a...

Predicted journal destinations